|
|
 Previous Article | Table of Contents | Next Article 
Clinicopathologic features and treatment outcome of children with large-
cell lymphoma and the t(2;5)(p23;q35)
JT Sandlund, CH Pui, WM Roberts, VM Santana, SW Morris, CW Berard, RE Hutchison, RC Ribeiro, H Mahmoud and WM Crist
Department of Hematology-Oncology, St Jude Children's Research Hospital,
Memphis, TN 38101.
The t(2;5)(p23;q35) was detected in 9 of the 18 cases of large-cell
lymphoma with an abnormal karyotype among 115 children with large-cell
lymphoma treated at St Jude Children's Research Hospital from 1975 to 1993.
When the cases containing the t(2;5) were classified according to the
National Cancer Institute Working Formulation, 7 were large-cell,
immunoblastic and 2 were diffuse large cell; according to the Kiel
classification system, 6 were anaplastic large cell, 2 immunoblastic, and 1
centroblastic. CD30 expression was documented in 6 of 8 cases tested. All
patients had nodal disease and 6 had extranodal involvement (bone in 4
cases and skin in 3). Eight of nine had advanced disease at diagnosis
(stage Ill in 7 and stage IV in 1). Complete remission (CR) was attained in
all patients and 6 remain in first CR for 19+ to 97+ months. Three
relapsed, but successfully obtained second remissions; 2 are 58+ and 80+
months after retrieval therapy for local recurrences, and 1 patient died of
recurrent disease. The t(2;5)(p23;q35) is associated with, but not limited
to, anaplastic histology, a CD30+ T- cell phenotype, advanced stage disease
with nodal (+/- extranodal) involvement, and chemosensitivity at diagnosis
and relapse.
Volume 84,
Issue 8,
pp. 2467-2471,
10/15/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Damm-Welk, K. Busch, B. Burkhardt, J. Schieferstein, S. Viehmann, I. Oschlies, W. Klapper, M. Zimmermann, J. Harbott, A. Reiter, et al.
Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma
Blood,
July 15, 2007;
110(2):
670 - 677.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Snyder
Resumption of high-dose methotrexate after methotrexate-induced nephrotoxicity and carboxypeptidase G2 use
Am. J. Health Syst. Pharm.,
June 1, 2007;
64(11):
1163 - 1169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Kutok and J. C. Aster
Molecular Biology of Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma
J. Clin. Oncol.,
September 1, 2002;
20(17):
3691 - 3702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Seidemann, M. Tiemann, M. Schrappe, E. Yakisan, I. Simonitsch, G. Janka-Schaub, W. Dorffel, M. Zimmermann, G. Mann, H. Gadner, et al.
Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90
Blood,
June 15, 2001;
97(12):
3699 - 3706.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L t. Berge, J. J Oudejans, G.-J. Ossenkoppele, K. Pulford, R. Willemze, B. Falini, A. Chott, and C. J L M Meijer
ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination
J. Clin. Pathol.,
June 1, 2000;
53(6):
445 - 450.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. B. Colleoni, J. A. Bridge, B. Garicochea, J. Liu, D. A. Filippa, and M. Ladanyi
ATIC-ALK: A Novel Variant ALK Gene Fusion in Anaplastic Large Cell Lymphoma Resulting from the Recurrent Cryptic Chromosomal Inversion, inv(2)(p23q35)
Am. J. Pathol.,
March 1, 2000;
156(3):
781 - 789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. ten Berge, D. F. Dukers, J. J. Oudejans, K. Pulford, G. J. Ossenkoppele, D. de Jong, J. F.M.M. Misere, and C. J.L.M. Meijer
Adverse Effects of Activated Cytotoxic T Lymphocytes on the Clinical Outcome of Nodal Anaplastic Large Cell Lymphoma
Blood,
April 15, 1999;
93(8):
2688 - 2696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Brugieres, M.C. L. Deley, H. Pacquement, Z. Meguerian-Bedoyan, M.J. Terrier-Lacombe, A. Robert, C. Pondarre, G. Leverger, C. Devalck, C. Rodary, et al.
CD30+ Anaplastic Large-Cell Lymphoma in Children: Analysis of 82 Patients Enrolled in Two Consecutive Studies of the French Society of Pediatric Oncology
Blood,
November 15, 1998;
92(10):
3591 - 3598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. U. Kuefer, A. T. Look, K. Pulford, F. G. Behm, P. K. Pattengale, D. Y. Mason, and S. W. Morris
Retrovirus-Mediated Gene Transfer of NPM-ALK Causes Lymphoid Malignancy in Mice
Blood,
October 15, 1997;
90(8):
2901 - 2910.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Mathew, W. G. Sanger, D. D. Weisenburger, M. Valentine, V. Valentine, D. Pickering, C. Higgins, M. Hess, X. Cui, D. K. Srivastava, et al.
Detection of the t(2; 5)(p23; q35) and NPM-ALK Fusion in Non-Hodgkin's Lymphoma by Two-Color Fluorescence In Situ Hybridization
Blood,
March 1, 1997;
89(5):
1678 - 1685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Pulford, L. Lamant, S. W. Morris, L. H. Butler, K. M. Wood, D. Stroud, G. Delsol, and D. Y. Mason
Detection of Anaplastic Lymphoma Kinase (ALK) and Nucleolar Protein Nucleophosmin (NPM)-ALK Proteins in Normal and Neoplastic Cells With the Monoclonal Antibody ALK1
Blood,
February 15, 1997;
89(4):
1394 - 1404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Krenacs, A. Wellmann, L. Sorbara, A. W. Himmelmann, E. Bagdi, E. S. Jaffe, and M. Raffeld
Cytotoxic Cell Antigen Expression in Anaplastic Large Cell Lymphomas of T- and Null-Cell Type and Hodgkin's Disease: Evidence for Distinct Cellular Origin
Blood,
February 1, 1997;
89(3):
980 - 989.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Sandlund, J. R. Downing, and W. M. Crist
Non-Hodgkin's Lymphoma in Childhood
N. Engl. J. Med.,
May 9, 1996;
334(19):
1238 - 1248.
[Full Text]
[PDF]
|
|
|
|
|
